Medacta Group

Medacta Group EBIT

The EBIT of Medacta Group (MOVE.SW) as of Oct 28, 2026 is 115.65 M EUR. In the previous year, EBIT was 90.83 M EUR — a change of 27.32% (higher).

EBIT

115.65 MEUR

YoY

27.32%

Last updated:

In 2025, Medacta Group's EBIT was 115.65 M EUR, a 27.32% increase from the 90.83 M EUR EBIT recorded in the previous year.

The Medacta Group EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT
Date
EBIT
Jan 1, 2023
74.44 M EUR
Jan 1, 2024
90.83 M EUR
Jan 1, 2025
115.65 M EUR
Jan 1, 2026 (e)
116.30 M EUR
Jan 1, 2027 (e)
140.36 M EUR
Jan 1, 2028 (e)
179.93 M EUR
Jan 1, 2029 (e)
168.14 M EUR
Jan 1, 2030 (e)
184.84 M EUR
The Medacta Group EBIT history
YEAREBITYoY
est184.84 MEUR+9.94%
est168.14 MEUR-6.55%
est179.93 MEUR+28.18%
est140.36 MEUR+20.69%
est116.30 MEUR+0.56%
115.65 MEUR+27.32%
90.83 MEUR+22.02%
74.44 MEUR+21.12%
61.46 MEUR+4.57%
58.78 MEUR+18.88%
49.44 MEUR+23.31%
40.10 MEUR-34.82%
61.51 MEUR+23.86%
49.66 MEUR+0.33%
49.50 MEUR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Medacta Group Revenue

Medacta Group Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
503.95 M EUR
74.44 M EUR
47.36 M EUR
Jan 1, 2024
583.07 M EUR
90.83 M EUR
72.89 M EUR
Jan 1, 2025
681.46 M EUR
115.65 M EUR
96.12 M EUR
Jan 1, 2026 (e)
753.33 M EUR
116.30 M EUR
94.64 M EUR
Jan 1, 2027 (e)
850.57 M EUR
140.36 M EUR
112.73 M EUR
Jan 1, 2028 (e)
952.68 M EUR
179.93 M EUR
132.51 M EUR
Jan 1, 2029 (e)
1.04 B EUR
168.14 M EUR
136.34 M EUR
Jan 1, 2030 (e)
1.12 B EUR
184.84 M EUR
150.49 M EUR

Medacta Group Margins

Medacta Group stock margins

The Medacta Group margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Medacta Group. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Medacta Group.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2023
69.02 %
14.77 %
9.40 %
Jan 1, 2024
68.51 %
15.58 %
12.50 %
Jan 1, 2025
64.77 %
16.97 %
14.11 %
Jan 1, 2026 (e)
64.77 %
15.44 %
12.56 %
Jan 1, 2027 (e)
64.77 %
16.50 %
13.25 %
Jan 1, 2028 (e)
64.77 %
18.89 %
13.91 %
Jan 1, 2029 (e)
64.77 %
16.22 %
13.15 %
Jan 1, 2030 (e)
64.77 %
16.54 %
13.47 %

Medacta Group Stock analysis

What does Medacta Group do? The Medacta Group SA is a leading global company in the development, manufacturing, and marketing of medical devices and implants for the orthopedic industry. The company was founded in 1999 by Swiss entrepreneur Alberto Siccardi and is headquartered in Switzerland. The Medacta Group SA has its origins in one person - Alberto Siccardi. As a former athlete and successful entrepreneur, he had a vision that he put into action. He founded the Medacta Group and began focusing on the development and manufacturing of innovative orthopedic devices and implants. The Medacta Group has an innovative business model because the company is able to handle everything from research and development to marketing and sales of its products. This means that Medacta combines all steps from idea to end product under one roof and has complete control over the entire process. The Medacta Group SA is divided into three business areas: orthopedics, spine, and sports medicine. In the orthopedic field, the company manufactures hip and knee joint implants, as well as shoulder and elbow implants. Medacta also offers technologies that help extend the lifespan of artificial joints. In the spine field, the company provides instruments and implants for spine surgery. Medacta has a high level of expertise in this field and is known for innovative products that contribute to improving patient treatment. In the sports medicine field, the Medacta Group offers solutions for sports injuries. The company has developed a wide range of technologies and products that accelerate the healing process and support rehabilitation. Some of Medacta's most well-known products are the AMIS (Anterior Minimally Invasive Surgery) hip joint system and the GMK (General Medacta Knee) knee joint system. The AMIS system is a minimally invasive procedure for hip joint surgery that aims to shorten rehabilitation time and reduce the risk of complications. The GMK system is an innovative knee joint system that allows natural joint mechanics and approximates the natural knee pivot point. Medacta has also developed a range of software solutions that support surgeons in the planning and execution of operations. These solutions provide detailed visualizations and allow for precise planning of procedures. In conclusion, the Medacta Group SA is a global leader in the development and manufacturing of medical devices and implants for orthopedics, spine, and sports medicine. The company has an innovative business model that allows for complete control of the entire manufacturing process. Through the development of innovative products and technologies, the Medacta Group supports the treatment and rehabilitation of patients worldwide. Medacta Group is one of the most popular companies on Eulerpool.

EBIT Details

Analyzing Medacta Group's EBIT

Medacta Group's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Medacta Group's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Medacta Group's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Medacta Group’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Medacta Group stock

EBIT of Medacta Group is 115.65 M EUR in 2025.

EBIT of Medacta Group changed from 90.83 M EUR to 115.65 M EUR, representing a 27.32% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT Medacta Group since 2006 – with annual values, charts, and detailed analysis.

"Earnings before interest and taxes", abbreviated as EBIT, is also referred to as the operating result of a company. It is a key figure that allows the profit to be assessed over a specific period of time, usually a fiscal year. Taxes and interest are not deducted from EBIT, making it suitable for international comparisons of different companies.

Net income
+ Tax expense
+ Interest expense and other financial expenses
- Interest income and other financial income
= EBIT (operating profit)

EBIT's EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT's Medacta Group historically and in real time.

The sales revenue is important for evaluating a stock.

EBIT is an acronym for "Earnings Before Interest and Tax" and represents a company's gross profit before taxes and interest are deducted. The EBIT amount is often used as a metric to evaluate a company.

History

The EBIT was originally introduced in the 1940s when the US Internal Revenue Service (IRS) passed a new tax law. This law required companies to calculate their profit before deducting taxes and interest on loans (or "interest and taxes"). Since then, the EBIT has been used as one of the key financial indicators in evaluating a company.

Usage

The EBIT can be used to assess a company by comparing its financial results to a benchmark or a comparative value. The EBIT is also used to determine how much the company's shareholders will receive from its operating income.

Calculation

EBIT is calculated by deducting taxes and interest on loans from the company's net profit. This amount can be calculated in various ways, but the most common method is as follows:

EBIT = Net profit + interest and taxes

Example: Eulerpool: Your source for quantitative stock data At Eulerpool, we are dedicated to providing you with comprehensive and accurate stock information. Our website offers a wide range of tools and features, including charts, stock lists, and more. Whether you are an experienced investor or just starting out, our platform is designed to meet your needs. With our in-depth analytics and algorithms, you can make informed decisions and stay ahead of the market. Explore our extensive collection of stocks, track their performance, and access real-time data. With Eulerpool, you can easily navigate the world of finance and monitor the stocks that matter to you. Join our community today and gain valuable insights into the world of stocks and investments. Sign up for free and discover the power of Eulerpool. Stay informed. Stay ahead. Eulerpool - your trusted partner in stock data.
Net profit of XYZ Co. = $1,000,000
Interest and taxes = $ 500,000
EBIT of XYZ Co. = $1,500,000

Application

The EBIT value is often used to determine and evaluate the financial stability of a company. The EBIT value can also be used to determine how much money a company can spend on investments or dividends.

Use of EBIT in stock investment

Investors use EBIT to determine if a stock is over- or undervalued. If a company has a high EBIT value, it may indicate that its stock is overvalued, as the profit it generates could be lower than what it would generate with a different stock.

Advantages of EBIT

EBIT is a helpful measure for determining the financial stability of a company. There are several advantages associated with using EBIT, such as:
- EBIT eliminates the impact of financing on the company's earnings.
- It is a useful measure for determining the profits that a company can distribute to its shareholders.
- It can be used to determine whether a stock is overvalued or undervalued.

Disadvantages of EBIT

There are also some disadvantages to using EBIT, such as:
- EBIT cannot be used as the sole measure to evaluate a company as it does not reflect the overall profit of the company.
- EBIT can be influenced by unforeseen events such as a tax increase.
- EBIT is not always a reliable indicator of a company's future profit development.

Conclusion

The EBIT is an important measure used to evaluate a company. It can be used to determine how much money a company can generate from its operational results and whether a stock is overvalued or undervalued. However, the EBIT also has some disadvantages as it does not reflect the overall profitability of a company and can be influenced by unforeseen events. Therefore, it is important to consider the EBIT in conjunction with other financial indicators to obtain a complete picture of the company.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Medacta Group

All Key Metrics — Medacta Group